Activation of cytotoxic T-cell receptor γδ T lymphocytes in response to specific stimulation in myelodysplastic syndromes

Haematologica

Volumn 93, Issue 3, 2008, Pages 381-389

  Kiladjian, Jean Jacques ^a,b,c   Visentin, Géraldine ^a   Viey, Emilie ^a   Chevret, Sylvie ^a   Eclache, Virginie ^b   Stirnemann, Jerome ^e   Bourhis, Jean Henri ^a   Chouaib, Salem ^d   Fenaux, Pierre ^b,c   Caignard, Anne ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL JEAN VERDIER   (France)

Author keywords

Cellular immunology; Innate immunity; Myelodysplasia

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PYROPHOSPHORIC ACID DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CELL FUNCTION; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; MALE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CLONE CELLS; DIPHOSPHATES; FEMALE; HUMANS; IMMUNOLOGIC SURVEILLANCE; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERFERON TYPE II; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTE SUBSETS;

EID: 40849127239     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11812     Document Type: Article

References (38)

1. Heaney M, Golde D. Myelodysplasia. N Engl J Med 1999; 340: 1649-60.
2. Hamblin T. Immunology of the myelodysplastic syndromes. In: Bennet JM, ed. The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York: Marcel Dekker; 2002. p. 65-7.
3. Hebbar M, Brouillard M, Wattel E, Decoulx M, Hatron PY, Devulder B, et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995; 9:731-3.
4. Hebbar M, Kozlowski D, Wattel E, Mastrini S, Dievart M, Duclos B, et al. Association between myelodysplastic syndromes and inflammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia 1997;11:2188-91.
5. Greenberg P, Young N, N Gatterman. Myelodysplastic syndromes. Hematology 2002; 1: 136-61.
6. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137:156-63.
7. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, et al. NK cells and the tumour microenvironment: implications for NK-cell function and antitumour activity. Trends Immunol 2003;24:603-9.
8. Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469-76.
9. Kiladjian JJ, Bourgeois E, Lobe I, Braun T, Visentin G, Bourhis JH, et al. Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes. Leukemia 2006;20:463-70.
10. Band H, Panchamoorthy G, Mclean J, Morita C, Ishikawa S, Modlin R, et al. Recognition of mycobacterial antigens by gamma delta T cells. Res Immunol 1990;141:645-51.
11. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 2001;167:5092-8.
12. Sicard H, Al Saati T, Delsol G, Fournie JJ. Synthetic phosphoantigens enhance human Vgamma9 Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 2001;7:711-22.
13. Gober H, Kistowska M, Angman L, Jeno P, Mori L, Libero GD. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
14. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96:384-92.
15. Kunzmann V, Wilhelm M. Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 2005;46:671-80.
16. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005;19:664-70.
17. Das H, Wang L, Kamath A, Bukowski J. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001; 98:1616-8.
18. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005;309:264-8.
19. Kapp JA, Kapp LM, McKenna KC. Gammadelta T cells play an essential role in several forms of tolerance. Immunol Res 2004;29:93-102.
20. Born WK, Jin N, Aydintug MK, Wands JM, French JD, Roark CL, et al. gammadelta T lymphocytesselectable cells within the innate system¿ combining dot below J Clin Immunol 2007;27:133-44.
21. Balbi B, Valle M, Oddera S, Giunti D, Manca F, Rossi G, et al. T-lymphocytes with gamma delta+ V delta 2+ antigen receptors are present in increased proportions in a fraction of patients with tuberculosis or with sarcoidosis. Am Rev Respir Dis 1993;148:1685-90.
22. Janis E, Kaufmann S, Schwartz R, Pardoll D. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 1989;244:713-6.
23. Sireci G, Espinosa E, Di Sano C, Dieli F, Fournie JJ, Salerno A. Differential activation of human gammadelta cells by nonpeptide phosphoantigens. Eur J Immunol 2001; 31:1628-1635.
24. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005;174:1338-47.
25. Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
26. Espinosa E, Belmant C, Pont F, Luciani B, Poupot R, Romagne F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem 2001;276:18337-44.
27. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med 2003;198:391-7.
28. Parker CM, Groh V, Band H, Porcelli SA, Morita C, Fabbi M, et al. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med 1990;171:1597-612.
29. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004;294:15-22.
30. de Witte T, Oosterveld M, Muus P. Autologous and allogeneic stem cell transplantation for myelodysplastic syndrome. Blood Rev 2007;21:49-59.
31. Maciejewski JP, Anderson S, Katevas P, Young NS. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol 1994; 87:227-34.
32. Marisavljevic D, Kraguljac N, Rolovic Z. Immunologic abnormalities in myelodysplastic syndromes: clinical features and characteristics of the lymphoid population. Med Oncol 2006;23: 385-92.
33. Giacomelli R, Cipriani P, Fulminis A, Barattelli G, Matucci-Cerinic M, D'Alo S, et al. Circulating g/d T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization. Clin Exp Immunol 2001;125: 310-5.
34. Alaibac M, Berti E, Chizzolini C, Fineschi S, Marzano AV, Pigozzi B, et al. Role of cellular immunity in the pathogenesis of autoimmune skin diseases. Clin Exp Rheumatol 2006;24:S14-9.
35. Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, et al. Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? Lupus 2000;9:333-7.
36. Re F, Poccia F, Donnini A, Bartozzi B, Bernardini G, Provinciali M. Skewed representation of functionally distinct populations of Vg9Vd2 T lymphocytes in aging. Exp Gerontol 2005;40:59-66.
37. Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vg9Vd2 naive, memory and effector T cell subsets. Eur J Immunol 2005;35:1764-72.
38. Lafont V, Loisel S, Liautard J, Dudal S, Sable-Teychene M, Liautard JP, et al. Specific signaling pathways triggered by IL-2 in human Vg9Va2 T cells: an amalgamation of NK and ab T cell signaling. J Immunol 2003; 171:5225-32.